Spectrum Pharmaceuticals News

However hard the market slams a stock, there's always the chance it'll come bouncing right back.

Zevalin Demonstrated Activity in Several Investigational Phase 2 Trials Presented at the 51st Annual Meeting of the American Society of Hematology Radio Immunotherapy Demonstrated Activity as Consolidation After Immuno Chemotherapy in Elderly DLBCL Patients and Follicular Lymphoma Patients ZEVALIN is Currently Indicated for the Treatment of ...

Spectrum Pharmaceuticals, Inc. , a commercial stage biotechnology company with a primary focus in oncology, today announced that clinical data on ZEVALIN was presented at the 51st Annual Meeting of the American Society of Hematology , which was held December 5-8, 2009 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

Featured Post Player a oefranklinqqa is looking for the next hot drug stock. a oeI think it is a dilemma for people whom invested in to make a love-hate comment of it: you cana t imagine how much people loved SPPI when it went up all the way from $0.9 level to $10, but I guess it would be as much as people hate it when its ZEVALIN got FDA approval ...

Spectrum Pharmaceuticals today announced that one of the two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target, having enrolled approximately 800 patients with non-invasive bladder cancer.

The NASDAQ OMX Group, Inc. announced today the results of the semi-annual re-ranking of the NASDAQ Biotechnology Index , which will become effective with the market open on Monday, November 23, 2009.

Together, we are all trying to build our fortune by finding well-run companies at bargain-basement prices.

Irvine-based Spectrum Pharmaceuticals is collaborating with Nippon Kayaku , a Tokyo-based general chemical firm, to develop and commercialize Spectrum's nonmuscle invasive bladder cancer therapy, apaziquone, in Asian territories.

Every day, the sun rises on Wall Street, and a plethora of professional analysts wake to issue new opinions on stocks.

Spectrum Pharmaceuticals , a commercial-stage biotechnology company with a primary focus in oncology, today announced that the Centers for Medicare & Medicaid Services finalized a policy to allow reimbursement for ZEVALIN , a CD20-directed radiotherapeutic antibody, in the Hospital Outpatient Prospective Payment System, based on the Average Sales ...

As quickly as drug makers can come down, they can bounce back with even greater efficiency and vice-versa. After taking a beating earlier this week, Acorda Therapeutics closed up over 40% on Thursday, October 15.

Several small-cap stocks were poised to move on above-average volume during Friday's session Spectrum Pharmaceuticals tumbled by $1.26, or 20.3%, to $4.95 in the premarket session after the Food and Drug Administration said that the company's application for its FUSILEV injection treatment for patients with advanced metastatic colorectal cancer did ...

As futures for the Dow Jones industrial average, the S&P 500 and the Nasdaq 100 are all pointing to a higher opening on Monday, it's important to note that we are starting a busy week of earnings, and that could be a mixed bag for traders and investors.

Spectrum Pharmaceuticals is still feeling the ill effects Monday of Friday's decision by the Food and Drug Administration to reject the company's request for an expanded approval of its current cancer drug Fusilev to include treatment for colon cancer.

IRVINE,A Calif. The Food and Drug Administration has rejected the approval application for a drug to treat colorectal cancer.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

The following stocks were among those that moved substantially or traded heavily Friday on the New York Stock Exchange.

Our analysts have issued free ratings reports on the following six companies: Leap Wireless International Inc.

The first rule of biotech: You do not talk about biotech. Oh wait. That's the first rule of Fight Club .

BENSALEM, Pa.-- --Law Offices of Howard G. Smith, representing investors of UCBH Holdings, Inc.